SEC Form 4 · accession 0001209191-15-049205
ZS Pharma, Inc. · ZSPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Farah Champsi
10% Owner
Daniel Janney
10% Owner
Guy P Nohra
Director · 10% Owner
Alta Partners VIII, L.P.
10% Owner
Alta Partners Management VIII, LLC
10% Owner
Period of report
May 29, 2015
Accepted (ET)
Jun 2, 2015 · 7:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001459266
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | May 29, 2015 | S | 124,865 | $58.63 | D | 3,105,225 | D | |
| Common StockF3,F2 | May 29, 2015 | S | 14,696 | $59.69 | D | 3,090,529 | D | |
| Common StockF4,F2 | Jun 1, 2015 | S | 72,520 | $58.00 | D | 3,018,009 | D | |
| Common StockF5,F2 | Jun 2, 2015 | S | 84,342 | $56.77 | D | 2,933,667 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $58.50 - $59.50, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.
- F2These shares were sold by Alta Partners VIII, L.P. ("APVIII"), the holder of record of the securities. Alta Partners Management VIII, LLC ("APMVIII") is the general partner of APVIII. Guy Nohra, Daniel Janney and Farah Champsi are managing directors of APMVIII and exercise shared voting and investment power with respect to the shares owned by APVIII. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein. Mr. Nohra is also a director of the issuer.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $59.51 - $59.94, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $57.60 - $58.50, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $56.50 - $57.05, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) to this Form 4.